Jump to: navigation, search
Systematic (IUPAC) name
2-diethylaminoethyl 4-amino-3-butoxy-benzoate
CAS number 99-43-4
ATC code D04AB03 S01HA02
PubChem 4633
DrugBank DB00892
Chemical data
Formula C17H28N2O3 
Mol. mass 308.41 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ?
Metabolism Esterases in blood plasma and liver
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes Topical

WikiDoc Resources for Oxybuprocaine


Most recent articles on Oxybuprocaine

Most cited articles on Oxybuprocaine

Review articles on Oxybuprocaine

Articles on Oxybuprocaine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Oxybuprocaine

Images of Oxybuprocaine

Photos of Oxybuprocaine

Podcasts & MP3s on Oxybuprocaine

Videos on Oxybuprocaine

Evidence Based Medicine

Cochrane Collaboration on Oxybuprocaine

Bandolier on Oxybuprocaine

TRIP on Oxybuprocaine

Clinical Trials

Ongoing Trials on Oxybuprocaine at Clinical Trials.gov

Trial results on Oxybuprocaine

Clinical Trials on Oxybuprocaine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Oxybuprocaine

NICE Guidance on Oxybuprocaine


FDA on Oxybuprocaine

CDC on Oxybuprocaine


Books on Oxybuprocaine


Oxybuprocaine in the news

Be alerted to news on Oxybuprocaine

News trends on Oxybuprocaine


Blogs on Oxybuprocaine


Definitions of Oxybuprocaine

Patient Resources / Community

Patient resources on Oxybuprocaine

Discussion groups on Oxybuprocaine

Patient Handouts on Oxybuprocaine

Directions to Hospitals Treating Oxybuprocaine

Risk calculators and risk factors for Oxybuprocaine

Healthcare Provider Resources

Symptoms of Oxybuprocaine

Causes & Risk Factors for Oxybuprocaine

Diagnostic studies for Oxybuprocaine

Treatment of Oxybuprocaine

Continuing Medical Education (CME)

CME Programs on Oxybuprocaine


Oxybuprocaine en Espanol

Oxybuprocaine en Francais


Oxybuprocaine in the Marketplace

Patents on Oxybuprocaine

Experimental / Informatics

List of terms related to Oxybuprocaine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Oxybuprocaine (INN), also known as benoxinate or BNX, is an ester-type local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine is sold by Novartis under the brand names Novesine or Novesin.

Safety for use in pregnancy and lactation has not been established.



Anaesthesia starts with a latency of 30 to 50 seconds and lasts for about 10 to 30 minutes, depending on perfusion. The drug is metabolised by esterases in blood plasma and liver.[2]

Adverse effects

When used excessively, oxybuprocaine like any other topical anesthetic used in the eye and on mucous membranes (like for example tetracaine, proxymetacaine and proparacaine) can cause irritation, hypersensitivity, anaphylaxis, irreversible corneal damage and even complete destruction of the cornea.[1][3] (Excessive use means several times a day during several days or even weeks.)


Oxybuprocaine is incompatible with silver and mercury salts, as well as basic substances. It also reduces the antimicrobial action of sulfonamides.[2]

See also


  1. 1.0 1.1 Drugs.com: Minims Oxybuprocaine Hydrochloride 0.4%
  2. 2.0 2.1 2.2 2.3 2.4 Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4. 
  3. PMID 17967152 (PubMed)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand